{"id":4582,"date":"2015-06-29T10:27:10","date_gmt":"2015-06-29T08:27:10","guid":{"rendered":"https:\/\/celonpharma.com\/?p=4582"},"modified":"2017-11-17T09:34:53","modified_gmt":"2017-11-17T09:34:53","slug":"celon-pharma-s-a-in-the-face-of-another-innovative-discovery","status":"publish","type":"post","link":"https:\/\/celonpharma.com\/en\/celon-pharma-s-a-in-the-face-of-another-innovative-discovery\/","title":{"rendered":"Celon Pharma S.A. in the face of another innovative discovery"},"content":{"rendered":"<p><strong>The scientific-business consortium lead by Celon Pharma S.A. received funding from the National Centre for Research and Development (NCRD) as part of the STRATEGMED programme for the development of another innovative project: &#8220;Development of novel biomarkers and innovative FGFR kinases inhibitor as an anti-cancer therapy&#8221; (CELONKO).<\/strong><\/p>\n<p>Celon Pharma will lead the &#8220;Development of modern novel biomarkers and development of an innovative FGFR kinases inhibitor for the treatment of neoplastic diseases an anti-cancer therapy&#8221; (CELONKO) project in cooperation with four other consortium members: National Institute of Tuberculosis and Lung Diseases in Warsaw, Military Institute of Medicine in Warsaw, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology and Medical University of Gda\u0144sk.<\/p>\n<p>The objective of the CELONKO project is preclinical and clinical development of\u00a0a new anti-cancer drug targeting fibroblast growth factor receptors (FGFRs). As\u00a0a result of R&amp;D works, a selective, small-molecule FGFR inhibitor will be obtained. It will be possible to use this drug in the fight against stomach cancer, bladder cancer and in treatment of squamous cell lung cancer.<\/p>\n<p>Another objective of the project will be the development of a diagnostic test for identifying patients with FGFR receptor aberrations. This will allow for selecting the patients who would benefit most from a personalized therapy based on\u00a0a selective FGFR inhibitor.<\/p>\n<p>&#8220;The main features distinguishing this innovative drug will be the targeted, profiled therapeutic effect and few adverse effects, that is everything which constitutes a cutting-edge solution in cancer treatment&#8221; \u2013 Maciej Wieczorek, CEO of Celon Pharma S.A. announced.<\/p>\n<p>So far, no FGFR kinase inhibitors have been registered, and the FGFR kinase inhibitor developed by Celon Pharma is more active and selective in studies on kinases and many cell lines.<\/p>\n<p>The total cost of the project is PLN 54,717,125, of which PLN 39,025,710 is financed by the National Centre for Research and Development.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The scientific-business consortium lead by Celon Pharma S.A. received funding from the National Centre for Research and Development (NCRD) as part of the STRATEGMED programme for the development of another innovative project: &#8220;Development of novel biomarkers and innovative FGFR kinases inhibitor as an anti-cancer therapy&#8221; (CELONKO). Celon Pharma will lead the &#8220;Development of modern novel<a class=\"excerpt-read-more float-right\" href=\"https:\/\/celonpharma.com\/en\/celon-pharma-s-a-in-the-face-of-another-innovative-discovery\/\" title=\"ReadCelon Pharma S.A. in the face of another innovative discovery\">Read more &raquo;<\/a><\/p>\n","protected":false},"author":11,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[27],"tags":[],"class_list":["post-4582","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Celon Pharma S.A. in the face of another innovative discovery - Celon Pharma<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/celonpharma.com\/en\/celon-pharma-s-a-in-the-face-of-another-innovative-discovery\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Celon Pharma S.A. in the face of another innovative discovery - Celon Pharma\" \/>\n<meta property=\"og:description\" content=\"The scientific-business consortium lead by Celon Pharma S.A. received funding from the National Centre for Research and Development (NCRD) as part of the STRATEGMED programme for the development of another innovative project: &#8220;Development of novel biomarkers and innovative FGFR kinases inhibitor as an anti-cancer therapy&#8221; (CELONKO). Celon Pharma will lead the &#8220;Development of modern novelRead more &raquo;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/celonpharma.com\/en\/celon-pharma-s-a-in-the-face-of-another-innovative-discovery\/\" \/>\n<meta property=\"og:site_name\" content=\"Celon Pharma\" \/>\n<meta property=\"article:published_time\" content=\"2015-06-29T08:27:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2017-11-17T09:34:53+00:00\" \/>\n<meta name=\"author\" content=\"S\u0142awomir Ni\u017cnik\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"S\u0142awomir Ni\u017cnik\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/celon-pharma-s-a-in-the-face-of-another-innovative-discovery\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/celon-pharma-s-a-in-the-face-of-another-innovative-discovery\\\/\"},\"author\":{\"name\":\"S\u0142awomir Ni\u017cnik\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/44c54386ed112173d6e8bcbeb6425338\"},\"headline\":\"Celon Pharma S.A. in the face of another innovative discovery\",\"datePublished\":\"2015-06-29T08:27:10+00:00\",\"dateModified\":\"2017-11-17T09:34:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/celon-pharma-s-a-in-the-face-of-another-innovative-discovery\\\/\"},\"wordCount\":317,\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/celon-pharma-s-a-in-the-face-of-another-innovative-discovery\\\/\",\"url\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/celon-pharma-s-a-in-the-face-of-another-innovative-discovery\\\/\",\"name\":\"Celon Pharma S.A. in the face of another innovative discovery - Celon Pharma\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#website\"},\"datePublished\":\"2015-06-29T08:27:10+00:00\",\"dateModified\":\"2017-11-17T09:34:53+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/44c54386ed112173d6e8bcbeb6425338\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/celon-pharma-s-a-in-the-face-of-another-innovative-discovery\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/celonpharma.com\\\/en\\\/celon-pharma-s-a-in-the-face-of-another-innovative-discovery\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/celon-pharma-s-a-in-the-face-of-another-innovative-discovery\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Celon Pharma S.A. in the face of another innovative discovery\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/\",\"name\":\"Celon Pharma\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/44c54386ed112173d6e8bcbeb6425338\",\"name\":\"S\u0142awomir Ni\u017cnik\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Celon Pharma S.A. in the face of another innovative discovery - Celon Pharma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/celonpharma.com\/en\/celon-pharma-s-a-in-the-face-of-another-innovative-discovery\/","og_locale":"en_US","og_type":"article","og_title":"Celon Pharma S.A. in the face of another innovative discovery - Celon Pharma","og_description":"The scientific-business consortium lead by Celon Pharma S.A. received funding from the National Centre for Research and Development (NCRD) as part of the STRATEGMED programme for the development of another innovative project: &#8220;Development of novel biomarkers and innovative FGFR kinases inhibitor as an anti-cancer therapy&#8221; (CELONKO). Celon Pharma will lead the &#8220;Development of modern novelRead more &raquo;","og_url":"https:\/\/celonpharma.com\/en\/celon-pharma-s-a-in-the-face-of-another-innovative-discovery\/","og_site_name":"Celon Pharma","article_published_time":"2015-06-29T08:27:10+00:00","article_modified_time":"2017-11-17T09:34:53+00:00","author":"S\u0142awomir Ni\u017cnik","twitter_card":"summary_large_image","twitter_misc":{"Written by":"S\u0142awomir Ni\u017cnik","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/celonpharma.com\/en\/celon-pharma-s-a-in-the-face-of-another-innovative-discovery\/#article","isPartOf":{"@id":"https:\/\/celonpharma.com\/en\/celon-pharma-s-a-in-the-face-of-another-innovative-discovery\/"},"author":{"name":"S\u0142awomir Ni\u017cnik","@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/44c54386ed112173d6e8bcbeb6425338"},"headline":"Celon Pharma S.A. in the face of another innovative discovery","datePublished":"2015-06-29T08:27:10+00:00","dateModified":"2017-11-17T09:34:53+00:00","mainEntityOfPage":{"@id":"https:\/\/celonpharma.com\/en\/celon-pharma-s-a-in-the-face-of-another-innovative-discovery\/"},"wordCount":317,"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/celonpharma.com\/en\/celon-pharma-s-a-in-the-face-of-another-innovative-discovery\/","url":"https:\/\/celonpharma.com\/en\/celon-pharma-s-a-in-the-face-of-another-innovative-discovery\/","name":"Celon Pharma S.A. in the face of another innovative discovery - Celon Pharma","isPartOf":{"@id":"https:\/\/celonpharma.com\/en\/#website"},"datePublished":"2015-06-29T08:27:10+00:00","dateModified":"2017-11-17T09:34:53+00:00","author":{"@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/44c54386ed112173d6e8bcbeb6425338"},"breadcrumb":{"@id":"https:\/\/celonpharma.com\/en\/celon-pharma-s-a-in-the-face-of-another-innovative-discovery\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/celonpharma.com\/en\/celon-pharma-s-a-in-the-face-of-another-innovative-discovery\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/celonpharma.com\/en\/celon-pharma-s-a-in-the-face-of-another-innovative-discovery\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/celonpharma.com\/en\/"},{"@type":"ListItem","position":2,"name":"Celon Pharma S.A. in the face of another innovative discovery"}]},{"@type":"WebSite","@id":"https:\/\/celonpharma.com\/en\/#website","url":"https:\/\/celonpharma.com\/en\/","name":"Celon Pharma","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/celonpharma.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/44c54386ed112173d6e8bcbeb6425338","name":"S\u0142awomir Ni\u017cnik"}]}},"_links":{"self":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/4582","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/comments?post=4582"}],"version-history":[{"count":1,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/4582\/revisions"}],"predecessor-version":[{"id":12090,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/4582\/revisions\/12090"}],"wp:attachment":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/media?parent=4582"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/categories?post=4582"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/tags?post=4582"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}